web analytics
16.3 C
Munich
Saturday, May 28, 2022

The Steady Rise of Generex Biotechnology Corporation (OTCMKTS:GNBT)

Generex Biotechnology Corporation (OTCMKTS: GNBT) was on the rise again as the rest of the markets dropped after the Company announced they have recieved a contract from chinese partners to develope a COVID-19 Vaccine using li-key peptide vaccines. Under the terms of the contract with the China Technology Exchange, Beijing Zhonghua Investment Fund Management Co., LTD., Biology Institute of Shandong Academy of Sciences and Sinotek-Advocates International Industry Development (Shenzhen) Co., LTD. include an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced

Microcapdaily has been reporting on GNBT for years, we said on January 17, 2015 – Generex Biotechnology Corporation (OTCMKTS:GNBT) is making a huge move up on record breaking volume after the stock hit a recent low of $0.0105. The move comes as a big welcome for GNBT shareholders who have endured steady declines since GNBT was over $0.25 a share back in 2012. Now that GNBT has reversed off a penny on huge volume and the Company announced an acquisition which puts them in the pot sector speculators are giving this one another look. GNBT is a stock with a history of explosive moves running from well under a dime to over $0.30 in 2012.

Generex Biotechnology Corporation (OTCMKTS: GNBT) is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. Generex is building a new kind of healthcare company that extends beyond traditional models providing support to physicians in an MSO network, and ongoing relationships with patients to improve the patient experience and access to optimal care.

In addition to advancing a legacy portfolio of immune-oncology assets, medical devices, and diagnostics, the Company is focused on an acquisition strategy of strategic businesses that complement existing assets and provide immediate sources of revenue and working capital. Recent acquisitions include a management services organization, a network of pharmacies, clinical laboratory, and medical device companies with new and approved products. GNBT newly formed, wholly-owned subsidiary, NuGenerex Distribution Solutions (NDS), integrates the company’s MSO network with a pharmacy network, clinical diagnostic lab, durable medical equipment company (DME-IQ) and dedicated call center.

To Find out the inside Scoop on GNBT Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

GNBT

On February 24 the dividend was paid out; shareholders received 2 to 5 stock dividend of Generex Biotechnology shares plus an additional 2 to 5 stock dividend of NuGenerex Immuno-Oncology shares. GNBT initially gaped and ran to $1 on the news before coming back down with the rest of the market.

Joe Moscato, President & CEO of Generex, said, “I would like to extend my congratulations and sincere thanks to our valued shareholders, because we can now officially declare that the stock dividends will be paid on Monday the 24th as FINRA. I would like to thank all of you for your patience and support of Generex throughout this process, which has delayed our plans for five months. We realize this delay has eroded share value, however, with the dividend paid, we are now we are poised for growth and success. With the dividend being paid next week, and our Generex S-1 registration statement filed, we can now execute fully on our plans. As a first step next week, we will be filing an S-1 for the spin out of NuGenerex Immuno-Oncology, with goal of listing directly onto the Nasdaq. With the S-1 funding, our subsidiaries can increase manufacturing, sales & marketing, and distribution of our revenue generating products. Our subsidiaries MediSource and Pantheon are already delivering sales growth of nearly 400% year over year, and we can now scale manufacturing to expand this growth. As Excellagen continues to gain approval from VAC committees in the VA system, we can expand the Olaregen sales force and implement our product line extension with Excellagen Aesthetics into the aesthetic dermatology market. We will turn on our public company MSO for orthopedic surgeons and podiatrists, and we will build NuGenerex Health in Arizona to deliver an integrated, multi-disciplinary diabetes management solution with our physician partners and continuing our efforts in diabetes, we will close on our acquisition of ALTuCELL, which is initiating human clinical trials of implanted cellular therapy using Altucaps for the treatment of Type I diabetes. We are excited about our opportunities to deliver exceptional value to our shareholders in 2020 as we achieve the success that we envisioned when we took over the company three years ago.”

On the coronavisur contract ceo Joe Mr. Moscato said, “Our subsidiary NuGenerex Immuno-Oncology has developed Ii-Key peptide vaccines against several potentially pandemic viruses, including bird flu, swine, flu, HIV, and a previous coronavirus, SARS. This wealth of experience has enabled us to develop a standardized protocol for rapid vaccine development, so we are positioned to respond in the event of a new, emerging pathogen. Our partners in China have recognized the power of our Ii-Key platform and have delivered this contract to establish a collaboration to combat the COVID-19 epidemic, and we are excited to begin the work.”

We have a Monster Pick Coming. Subscribe Right Now!

Currently trading at a $29 million market valuation GNBT is fully reporting and has $52 million in assets including $38 million in goodwill and over $24 million in current liabilities. The Company also boasts strong sales reporting $721k in revenues for the 3 months ended October 31, 2019. GNBT just reported the successful completion of the FINRA review process for the dividend and the Company just  recieved a contract from chinese partners to develope a COVID-19 Vaccine using li-key peptide vaccines which includes  an upfront payment of $1 million to initiate the project work in the United States, a $5 million licensing fee for the Ii-Key technology, payment by the Chinese consortium for all costs and expenses related to the development of a COVID-19 vaccine, and a 20% royalty on each dose of vaccine produced. We will be updating GNBT as events unfold so make sure you are subscribed to Microcapdaily so you know what is going on with GNBT.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in GNBT either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.